5-((4-chlorophenoxy)methyl)furan-2-carbaldehyde | 438219-08-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-((4-chlorophenoxy)methyl)furan-2-carbaldehyde
• 英文别名: 5-CMFC；5-[(4-Chlorophenoxy)methyl]furan-2-carbaldehyde
• CAS: 438219-08-0
• 化学式: C₁₂H₉ClO₃
• mdl: MFCD02253937
• 分子量: 236.655
• InChiKey: AXNCLMMSMBLUBF-UHFFFAOYSA-N

物化性质

• 沸点：
  381.8±37.0 °C(Predicted)
• 密度：
  1.310±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] 2 - SUBSTITUTED HETEROCYCLIC COMPOUNDS AND ANTITUMOR COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSES HETEROCYCLIQUES SUBSTITUES EN POSITION 2 ET COMPOSITION ANTITUMORALE RENFERMANT LESDITS COMPOSES
  申请人：CHONG KUN DANG PHARM CORP

  公开号：WO2004037808A1

  公开（公告）日：2004-05-06

  The present invention relates with 2-substituted heterocyclic compounds and antitumor composition comprising the same. The compound according to the present invention exhibits superior effect as telomerase inhibitor based on new mechanism (terlomere-terlomerase) which can resolve the problems occurring at the time of using chemotherapeutics, i.e side effects and cross resistance between related mechanism on using chemotherapeutics. In addition, the antitumor composition comprising the compound of the present invention exhibits superior effect in inhibiting the growth of cancer cell.

  本发明涉及2-取代杂环化合物和包括其在内的抗肿瘤组合物。根据本发明的化合物基于新机制（端粒酶-端粒酶）表现出优越的端粒酶抑制剂效果，可以解决在使用化疗药物时出现的问题，即副作用和化疗药物之间相关机制的交叉耐药性。此外，包括本发明化合物的抗肿瘤组合物表现出优越的抑制癌细胞生长的效果。
• Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives
  申请人：VIRGINIA COMMONWEALTH UNIVERSITY

  公开号：US10875834B2

  公开（公告）日：2020-12-29

  Prodrugs and derivatives of 5-hydoxymethyl-2-furfural (5-HMF) with protected or modified aldehyde and/or alcohol moieties are provided. The prodrugs or derivatives exhibit increased bioavailability, e.g. due to having extended half-lives in circulation. The drugs are therefore administered i) at lower doses and/or ii) less frequently than 5-HMF, while still maintaining the beneficial therapeutic effects of 5-HMF.

  5-hydoxymethyl-2-furfural (5-HMF) 的原药和衍生物具有受保护或修饰的醛和/或醇分子。这些原药或衍生物具有更高的生物利用度，例如由于其在血液循环中的半衰期更长。因此，与 5-HMF 相比，这些药物 i) 给药剂量更低和/或 ii) 给药次数更少，同时仍能保持 5-HMF 的有益治疗效果。